A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease

被引：269

作者：

Farlow, M

Anand, R

Messina, J

Hartman, R

Veach, J

机构：

[1] Indiana Univ, Sch Med, Dept Neurol, Indianapolis, IN 46202 USA

[2] Novartis Pharmaceut Corp, Dept Med Affairs CNS, E Hanover, NJ USA

[3] Novartis Pharmaceut Corp, Dept Stat, E Hanover, NJ USA

来源：

EUROPEAN NEUROLOGY | 2000年 / 44卷 / 04期

关键词：

cholinesterase inhibitor; rivastigmine; clinical trial; Alzheimer's disease;

D O I：

10.1159/000008243

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713; Exelon(R)), in patients with mild to moderately severe Alzheimer's disease was evaluated in a 26-week open-label extension of a 26-week, double-blind, placebo-controlled study. By 52 weeks, patients originally treated with 6-12 mg/day rivastigmine had significantly better cognitive function than patients originally treated with placebo. Copyright (C) 2000 S. Karger AG., Basel.

引用

页码：236 / 241

页数：6

共 10 条

[1]

[Anonymous], 1998, Int J Geriatr Psychopharmacol

[2]

Cutler NR, 1998, ACTA NEUROL SCAND, V97, P244

[3] Cholinergic markers in elderly patients with early signs of Alzheimer disease [J].

Davis, KL ;

Mohs, RC ;

Marin, D ;

Purohit, DP ;

Perl, DP ;

Lantz, M ;

Austin, G ;

Haroutunian, V .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (15) :1401-1406

[4]

ENZ A, 1993, PROG BRAIN RES, V98, P431

[5]

KRAMERGINSBERG E, 1988, PSYCHOPHARMACOL BULL, V24, P458

[6] Observations and suggestions on antidementia drug development [J].

Leber, P .

ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 1996, 10 :31-35

[7]

LEBER P, 1997, ALZHEIMER DIS ASS S5, V11, P10

[8]

ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356

[9] Efficacy and safety of rivastigmine in patients with Alzheimer's disease:: international randomised controlled trial [J].

Rösler, M ;

Anand, R ;

Cicin-Sain, A ;

Gauthier, S ;

Agid, Y ;

Dal-Bianco, P ;

Stähelin, HB ;

Hartman, R ;

Gharabawi, M .

BMJ-BRITISH MEDICAL JOURNAL, 1999, 318 (7184) :633-638

[10]

STERN RG, 1994, AM J PSYCHIAT, V151, P390

← 1 →